AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 61 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $246,000 | -48.0% | 106,810 | +7.4% | 0.00% | – |
| Q4 2021 | $473,000 | -40.2% | 99,477 | 0.0% | 0.00% | – |
| Q3 2021 | $791,000 | +7.3% | 99,477 | -6.0% | 0.00% | – |
| Q2 2021 | $737,000 | -16.1% | 105,779 | -4.5% | 0.00% | – |
| Q1 2021 | $878,000 | -0.8% | 110,783 | -1.5% | 0.00% | – |
| Q4 2020 | $885,000 | +18.0% | 112,424 | +6.4% | 0.00% | – |
| Q3 2020 | $750,000 | -25.5% | 105,653 | -2.9% | 0.00% | – |
| Q2 2020 | $1,007,000 | +255.8% | 108,846 | +79.7% | 0.00% | – |
| Q1 2020 | $283,000 | -37.9% | 60,560 | +1.6% | 0.00% | – |
| Q4 2019 | $456,000 | -0.7% | 59,621 | 0.0% | 0.00% | – |
| Q3 2019 | $459,000 | +12.2% | 59,621 | 0.0% | 0.00% | – |
| Q2 2019 | $409,000 | +13.9% | 59,621 | +33.9% | 0.00% | – |
| Q1 2019 | $359,000 | +16.2% | 44,511 | +8.1% | 0.00% | – |
| Q4 2018 | $309,000 | +6.6% | 41,160 | +35.8% | 0.00% | – |
| Q3 2018 | $290,000 | -9.7% | 30,300 | 0.0% | 0.00% | – |
| Q2 2018 | $321,000 | – | 30,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $532,000 | 6.17% |
| Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
| GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
| Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
| Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
| Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
| Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
| Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |